Danaher Co. (NYSE:DHR) Shares Sold by Apollon Wealth Management LLC

Apollon Wealth Management LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 2.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,287 shares of the conglomerate’s stock after selling 628 shares during the period. Apollon Wealth Management LLC’s holdings in Danaher were worth $4,886,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Wedge Capital Management L L P NC boosted its position in shares of Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares in the last quarter. Meridian Financial Partners LLC raised its position in Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after buying an additional 40 shares during the period. Kovack Advisors Inc. boosted its position in Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after acquiring an additional 41 shares during the period. Well Done LLC increased its holdings in shares of Danaher by 1.2% in the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after purchasing an additional 42 shares during the period. Finally, Waypoint Capital Advisors LLC boosted its holdings in shares of Danaher by 0.9% during the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock worth $1,257,000 after purchasing an additional 42 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 11.10% of the company’s stock.

Danaher Trading Down 1.5 %

NYSE:DHR opened at $206.92 on Friday. The firm has a market capitalization of $149.45 billion, a price-to-earnings ratio of 39.19, a PEG ratio of 2.68 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1-year low of $205.79 and a 1-year high of $281.70. The business’s 50-day moving average price is $232.72 and its two-hundred day moving average price is $251.79.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm posted $2.09 EPS. On average, equities analysts expect that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.52%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.45%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Scotiabank started coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Raymond James reaffirmed a “market perform” rating on shares of Danaher in a research note on Monday, February 3rd. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a research note on Friday, December 13th. Barclays decreased their target price on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $277.00 target price (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.